" "

Reports

Would you like to receive stakeholder email notices about changes to the Preferred Drug Lists?

Request updates

Quarterly Washington Preferred Drug Lists

2017

Quarter One

2016

 Quarter Four

Drug class updates

Below are the Therapeutic Interchange Program announcements and updates to drug classes covered under the Washington Preferred Drug List.

Drug status on the PDL

Defining a drug’s “preferred” or “non-preferred” status on the PDL:

  • A “preferred” drug on the PDL is not subject to the Therapeutic Interchange Program (TIP).
  • A “non-preferred” drug on the PDL is subject to TIP when it is included in a Drug Effectiveness Review Project (DERP) report.
  • If a drug is part of a PDL drug class, but it has not been reviewed by DERP, it is considered "non-preferred". It is not subject to TIP or dispense as written, and will be covered according to each program's benefit design.

Selection process of preferred drugs on the PDL

Contact

For archived announcements on a drug class
Leta Evaskus
Email:
leta.evaskus@hca.wa.gov
Phone: 206-521-2029